Over the years, the global pharmaceutical market maintained rapid growth momentum: the 20th century 50's and 70's, the world's pharmaceutical market, the average annual growth rate of 13.8%, 8.5% for the 80's, 90's growth started to slow down But sales are still from 205.8 billion U.S. dollars in 1991 increased to 565.9 billion U.S. dollars in 2005, far higher than the growth rate of the global economy. Global pharmaceutical market to set such an impressive performance with the new drugs are a large number are inseparable, no doubt, from the 80s of last century since a large number of drugs available in the international arena to promote the global pharmaceutical market is the driving force behind rapid growth. In recent years, diabetes, HIV, hepatitis C, particularly in the field of cancer treatment, many pharmaceutical companies invest huge sums of money. Some analysts boldly predicted in the next 10 years, in many of these areas will be the birth of new drugs, treatment will have a revolutionary change. It is estimated that one DPP-4, MK-0518, Tykerb, Telaprevir and other drugs, it is likely that tomorrow's "blockbuster." Although the risk of drug development targeting much higher than the generic R & D, but this article may be able to find ways to cure diseases, new nemesis, and even help the pharmaceutical companies unfavorable situation in the environment of confidence today, while reshaping reaps huge profits. Therefore, the road twists and turns Unfortunate though, the future remains full of light. New drugs is the pharmaceutical industry a source of living water. In 2007, people look to new drug development in 2006 of 32 online drug compounds to large pharmaceutical companies to fill the shortage of products online. However, these through targeted drug design, the wind investment house had really high hopes for the compound-listed at 2007 or smooth him jumped onto the next few years come out? It remains to be seen. Hypoglycemic agents: gather together Diabetes, the latest focus of the field in October 2006 FDA approval of Januvia, the drug that Merck developed a new class of hypoglycemic agents DDP-4 (dipeptidyl peptidase -4) The first oral inhibitor drugs, can improve the patient's own ability to lower blood sugar levels, while overcoming the TZDs (thiazolidinediones, ketones drugs) will increase the weight of the problem of patients and reduce the suffering of patients. The new drugs can prevent DDP-4 enzyme blocked incretin. Incretin can promote insulin secretion, inhibit glucagon release, thus promoting the body's blood sugar levels to reduce their own production. It is worth mentioning that the drug is at work with the blood sugar rises, so does not produce insulin or other drugs, side effects of low blood sugar. This new mechanism has also not been effectively controlled blood sugar in diabetic patients with an important choice. According to related statistics, there are 30 pharmaceutical companies active in the development of online DPP-4 drugs in the figure. There is no doubt that Merck's Januvia is the leader of such drugs. Novartis's Galvus Although still in FDA approval stage, but analysts believe that the listing of its hegemony, together with the strength and Januvia, and that two drug sales are expected to reach 2 billion to 30 billion dollars. Over the years, the global pharmaceutical market maintained rapid growth momentum: the 20th century 50's and 70's, the world's pharmaceutical market, the average annual growth rate of 13.8%, 8.5% for the 80's, 90's growth started to slow down But sales are still from 205.8 billion U.S. dollars in 1991 increased to 565.9 billion U.S. dollars in 2005, far higher than the growth rate of the global economy. Global pharmaceutical market to set such an impressive performance with the new drugs are a large number are inseparable, no doubt, from the 80s of last century since a large number of drugs available in the international arena to promote the global pharmaceutical market is the driving force behind rapid growth. In recent years, diabetes, HIV, hepatitis C, particularly in the field of cancer treatment, many pharmaceutical companies invest huge sums of money. Some analysts predict bold, the next 10 years, in these areas will be the birth of many new drugs, treatment will have a revolutionary change. It is estimated that one DPP-4, MK-0518, Tykerb, Telaprevir and other drugs, it is likely that tomorrow's "blockbuster." Although the risk of drug development targeting much higher than the generic R & D, but this article may be able to find ways to cure diseases, new nemesis, and even to help pharmaceutical companies unfavorable situation in the environment of confidence today, while reshaping reaps huge profits. Therefore, the road twists and turns Unfortunate though, the future remains full of light. New drugs is the pharmaceutical industry a source of living water. In 2007, people look to new drug development in 2006 of 32 online drug compounds to large pharmaceutical companies to fill the shortage of products online. However, these through targeted drug design, the wind investment house compounds have high hopes really got it in 2007 or smooth him jumped onto the next few years appeared? It remains to be seen. The e-commerce company in China offers quality products such as dual sim unlocked cell phones , dual sim cdma phone Manufacturer, and more. For more , please visit dual sims phones today!
Related Articles -
dual sim unlocked cell phones, dual sim cdma phone Manufacturer,
|